Related references
Note: Only part of the references are listed.Characteristics and Outcome of AKT1E17K_Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry
Lillian M. Smyth et al.
CANCER DISCOVERY (2020)
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
N. C. Turner et al.
ANNALS OF ONCOLOGY (2019)
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.
Robert Hugh Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial
Joseph D. Khoury et al.
CLINICAL CANCER RESEARCH (2018)
AKT Inhibition in Solid Tumors With AKT1 Mutations
David M. Hyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial Molecular Analysis for Therapy Choice Clinical Trial
Chih-Jian Lih et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
AKT in cancer: new molecular insights and advances in drug development
Prabhjot S. Mundi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
Ricardo Ribas et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2015)
MAGI3-AKT3 fusion in breast cancer amended
Juan-Miguel Mosquera et al.
NATURE (2015)
NCI-MATCH trial pushes cancer umbrella trial, paradigm
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2015)
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Sequence analysis of mutations and translocations across breast cancer subtypes
Shantanu Banerji et al.
NATURE (2012)
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers
Chaitali Parikh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
Qing-Bai She et al.
CANCER CELL (2010)
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kevin Kalinsky et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
Perturbations of the AKT signaling pathway in human cancer
DA Altomare et al.
ONCOGENE (2005)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Share Paper
